Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Open Access
- 20 May 2022
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 3 (8) , 100335
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Merck Sharp and Dohme United Kingdom
- Genentech
- Les Laboratories Pierre Fabre
- GlaxoSmithKline
- ACEA Biosciences
- Johnson and Johnson
- Angelini Pharma
- Takeda Pharmaceutical Company
- Pfizer
- Janssen Pharmaceutica
- Israel Cancer Research Fund
- Roche
- Daiichi-Sankyo
- Amgen
- Sanofi
- Eisai
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Eli Lilly and Company
- Clovis Oncology
- Merck
- Fresenius Kabi (EP19305434.3)
- Bristol Myers Squibb Foundation
- Novartis
- G1 Therapeutics
This publication has 10 references indexed in Scilit:
- A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryJournal of Thoracic Oncology, 2022
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta VariantsJAMA, 2022
- SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer AgentsJAMA Oncology, 2022
- Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous WavesJAMA, 2021
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature, 2021
- Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine DosesJournal of Thoracic Oncology, 2021
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studyThe Lancet, 2021
- Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumorsNature Medicine, 2021
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyThe Lancet Oncology, 2020